Jason Wallach

Last updated
Jason Wallach
Born1987 (age 37–38) [1] [2]
Alma mater Indiana University of Pennsylvania; University of the Sciences
Occupation(s) Pharmacologist; Assistant professor
Years active2009–present [3] [4]
Employer(s) Saint Joseph's University; Philadelphia College of Pharmacy
Website https://directory.sju.edu/jason-wallach
https://www.wallachlab.com/

Jason Wallach (born 1987) is an American pharmacologist who studies psychedelic drugs and other hallucinogens. [5] [2] [1] He is an assistant professor at Saint Joseph's University's Philadelphia College of Pharmacy. [2] [1]

In August 2020, Wallach began a partnership with the pharmaceutical company Compass Pathways for his research lab to develop novel psychedelic drugs as therapeutics. [5] [2] [1] [6] Hamilton Morris, a psychedelic journalist and the host of Hamilton's Pharmacopeia , works as a chemist in Wallach's lab. [1] [6]

Wallach graduated from Indiana University of Pennsylvania with his bachelor's degree in cell and molecular biology in 2008 and graduated with his Doctor of Philosophy degree in pharmacology and toxicology from the University of the Sciences in 2014. [5] [2] [7]

In 2023, Wallach, Morris, and other colleagues published a key paper characterizing the serotonin 5-HT2A receptor intracellular signaling cascades mediating the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. [8] [9] [10]

References

  1. 1 2 3 4 5 Wood, Sam (15 February 2021). "Envisioning a psychedelic future for Philadelphia's USciences as it pairs with Compass Pathways for a Drug Discovery Center". inquirer.com. Archived from the original on 15 February 2021. Retrieved 28 January 2025.
  2. 1 2 3 4 5 Ben Seal (May 2024). "A Psychedelic Renaissance". Saint Joseph's University Magazine. Retrieved 28 January 2025.
  3. ↑ Wallach JV (January 2009). "Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception". Med Hypotheses. 72 (1): 91–4. doi:10.1016/j.mehy.2008.07.052. PMID   18805646.
  4. ↑ Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Test Anal. 6 (7–8): 614–632. doi:10.1002/dta.1620. PMID   24678061.
  5. 1 2 3 Semley, John (26 July 2022). "The High-Stakes Race to Engineer New Psychedelic Drugs". WIRED. Archived from the original on 26 December 2024. Retrieved 28 January 2025.
  6. 1 2 "Psychedelic Compounds are Focus of USciences Lab". Newsroom. 18 October 2021. Retrieved 9 January 2025.
  7. ↑ "Jason V Wallach". University Directory. Retrieved 28 January 2025.
  8. ↑ Lomte, Tarun Sai (19 December 2023). "Scientists design non-hallucinogenic psychedelic treatments potentially accelerating research on mental health benefits". News-Medical. Retrieved 28 January 2025.
  9. ↑ "Trip or treat?". EurekAlert!. 15 December 2023. Retrieved 28 January 2025.
  10. ↑ Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, Hennessey JJ, Bock HA, Anderson EI, Sherwood AM, Morris H, de Klein R, Klein AK, Cuccurazzu B, Gamrat J, Fannana T, Zauhar R, Halberstadt AL, McCorvy JD (December 2023). "Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential". Nat Commun. 14 (1): 8221. doi:10.1038/s41467-023-44016-1. PMC   10724237 . PMID   38102107.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.